NXL

Nexalin Technology, Inc. Common Stock (NXL) | Rumor.io

Nexalin Technology

NXL

Attention (50-day avg)0%

Attention rank (50-day avg)#2,454

Bullish sentiment (50-day avg)69%

Price to earnings ratio-8.54

Market capitalization3.7M

Earnings per share-13.8

Dividend yield (TTM)—

Revenue (annual)301.6K

Net income (annual)-8.2M

Social

What share of all stock conversation is about NXL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

Aug 31

Nexalin Technology, Inc. (NXL) stock price has surged 15.68% since an alert at 9:43am EDT, with multiple posts highlighting its momentum and catalysts.
The stock has been halted with a code LUDP, and there is a risk of Nasdaq delisting due to its market cap being less than $5 million.
NXL's price has also been impacted by a merger catalyst with Nuvation Bio, resulting in a near-vertical price spike from a penny-stock dormancy on massive volume.

Generated by AI

Sentiment

Of the messages about NXL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +38.46	86.37% -11.49
Bearish	—	—	0% -38.46	13.63% +11.49

Bullish· May 22

$NXL is expected to boom with FDA approval for Alzheimer treatment, potentially similar to the performance of $PCLA.
The company's small float and strong catalysts make it a promising investment opportunity for a potential run.
$NXL has shown significant upside potential, with one algorithm predicting a 400% run from its current price.

Bearish· May 22

The asset's price has dropped 10% in 20 minutes, indicating high volatility and potential instability.
The company's stock is prone to sudden and significant price drops, making it a high-risk investment.
The asset's performance is characterized by rapid and unpredictable price movements, making it challenging for investors to anticipate and react to market changes.

Generated by AI

Topics

Of the messages about NXL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	25%	41.55%
Technical Analysis	—	—	75%	27.57%
Analysts	—	—	0%	11.27%
Controversies	—	—	0%	3.42%
Earnings	—	—	0%	0%
Macro	—	—	0%	16.2%

Announcements· Feb 5

Nexalin Technology ($NXL) launches NeuroCare, an AI-driven virtual clinic for remote, physician-monitored neurotherapy at home, in collaboration with UC San Diego.
The virtual clinic aims to expand patient access, reduce costs, and break down treatment stigma for brain health disorders such as Alzheimer's, mood disorders, TBI, and PTSD.
Nexalin's NeuroCare platform integrates with the company's HALO Gen-3 headset, delivering Deep Intracranial Frequency Stimulation (DIFS) technology, and offers a subscription-based model for at-home neurostimulation therapy.

Technical Analysis· Oct 8

$NXL is trading in a range-bound consolidation between $1.50 and $1.67 under the VWAP, with the author keeping this on watch for any shift in volume or range break.
A double bottom pattern is forming in $NXL, with the author suggesting it could be a strong bullish signal if the stock holds above $1.40.
The author is expecting a potential breakout in $NXL, possibly driven by strong SYNC device data, with a target of $1.70 and a Fibonacci retracement level of $1.90.

Generated by AI

Community

Of the messages about NXL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.5%	32.65%
Newcomers	—	0%	37.5%	67.35%

Regulars· Oct 8

The regulars are watching $NXL closely, particularly if it can hold above $1.40, with some seeing potential for a parabolic move if it reaches $1.95 or higher.
The recent clinical results announced by Nexalin Technology, Inc. have been well-received, with some participants highlighting the positive implications for the stock.
The stock's current range-bound behavior between $1.50 and $1.67 is being closely monitored, with some participants waiting for a shift in volume or a break in this range to determine the next course of action.

Newcomers· Aug 31

$NXL has seen a significant price spike of 2843% after a merger catalyst was triggered, making it a potentially attractive stock for investors.
The stock's market capitalization is now at risk of being delisted from Nasdaq if it falls below $5 million, which could have a negative impact on its value.
There is ongoing debate among investors about whether to buy or sell Nexalin Technology stock, with some considering it a good opportunity for investment and others expressing concerns about its volatility.

Generated by AI

News

Nexalin appoints Robert DiTota as senior strategic advisor

21h agoInvesting.com

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

22h agoYahoo! Finance Canada

Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.

18d agoYahoo Finance

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three m

26d agoca.finance.yahoo.com

Nexalin Announces 1-for-30 Reverse Stock Split Approval

Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Nexalin Technology approves 1-for-30 reverse stock split

1mo agoInvesting.com

Also Discussed

Investors talking about NXL also mention

#	Name	Attention
1	RVPH - Reviva Pharmaceuticals Holdings, Inc.	——
2	TPHS - Trinity Place Holdings Inc.	——
3	CMAX - CareMax, Inc.	——
4	Calidi Biotherapeutics, Inc.CLDI	0%0
5	Cardio Diagnostics Holdings, Inc.CDIO	0%0
6	Aligos Therapeutics, Inc.ALGS	0%new
7	Prestige Consumer Healthcare Inc.PBH	0%0
8	The Eastern CompanyEML	0%new
9	Telos CorporationTLS	0%+0
10	ZipRecruiter Inc.ZIP	0%0

Nexalin Technology, Inc. Common Stock

Healthcare
Medical Devices

Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions. Nexalin Technology serves clinicians and patients through products intended for use in medical settings and, in some cases, at home under professional guidance. Its product portfolio is centered on neuromodulation therapies that aim to provide drug-free treatment options within the healthcare and medical technology markets. The stock is used by investors to track ownership in a specialized healthcare company operating at the intersection of medical devices, digital health, and neurotechnology.

Website

Location

1776 Yorktown

Houston, TX, 77056

United States

Social

What share of all stock conversation is about NXL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

Aug 31

Nexalin Technology, Inc. (NXL) stock price has surged 15.68% since an alert at 9:43am EDT, with multiple posts highlighting its momentum and catalysts.
The stock has been halted with a code LUDP, and there is a risk of Nasdaq delisting due to its market cap being less than $5 million.
NXL's price has also been impacted by a merger catalyst with Nuvation Bio, resulting in a near-vertical price spike from a penny-stock dormancy on massive volume.

Generated by AI

Sentiment

Of the messages about NXL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +38.46	86.37% -11.49
Bearish	—	—	0% -38.46	13.63% +11.49

Bullish· May 22

$NXL is expected to boom with FDA approval for Alzheimer treatment, potentially similar to the performance of $PCLA.
The company's small float and strong catalysts make it a promising investment opportunity for a potential run.
$NXL has shown significant upside potential, with one algorithm predicting a 400% run from its current price.

Bearish· May 22

The asset's price has dropped 10% in 20 minutes, indicating high volatility and potential instability.
The company's stock is prone to sudden and significant price drops, making it a high-risk investment.
The asset's performance is characterized by rapid and unpredictable price movements, making it challenging for investors to anticipate and react to market changes.

Generated by AI

Topics

Of the messages about NXL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	25%	41.55%
Technical Analysis	—	—	75%	27.57%
Analysts	—	—	0%	11.27%
Controversies	—	—	0%	3.42%
Earnings	—	—	0%	0%
Macro	—	—	0%	16.2%

Announcements· Feb 5

Nexalin Technology ($NXL) launches NeuroCare, an AI-driven virtual clinic for remote, physician-monitored neurotherapy at home, in collaboration with UC San Diego.
The virtual clinic aims to expand patient access, reduce costs, and break down treatment stigma for brain health disorders such as Alzheimer's, mood disorders, TBI, and PTSD.
Nexalin's NeuroCare platform integrates with the company's HALO Gen-3 headset, delivering Deep Intracranial Frequency Stimulation (DIFS) technology, and offers a subscription-based model for at-home neurostimulation therapy.

Technical Analysis· Oct 8

$NXL is trading in a range-bound consolidation between $1.50 and $1.67 under the VWAP, with the author keeping this on watch for any shift in volume or range break.
A double bottom pattern is forming in $NXL, with the author suggesting it could be a strong bullish signal if the stock holds above $1.40.
The author is expecting a potential breakout in $NXL, possibly driven by strong SYNC device data, with a target of $1.70 and a Fibonacci retracement level of $1.90.

Generated by AI

Community

Of the messages about NXL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.5%	32.65%
Newcomers	—	0%	37.5%	67.35%

Regulars· Oct 8

The regulars are watching $NXL closely, particularly if it can hold above $1.40, with some seeing potential for a parabolic move if it reaches $1.95 or higher.
The recent clinical results announced by Nexalin Technology, Inc. have been well-received, with some participants highlighting the positive implications for the stock.
The stock's current range-bound behavior between $1.50 and $1.67 is being closely monitored, with some participants waiting for a shift in volume or a break in this range to determine the next course of action.

Newcomers· Aug 31

$NXL has seen a significant price spike of 2843% after a merger catalyst was triggered, making it a potentially attractive stock for investors.
The stock's market capitalization is now at risk of being delisted from Nasdaq if it falls below $5 million, which could have a negative impact on its value.
There is ongoing debate among investors about whether to buy or sell Nexalin Technology stock, with some considering it a good opportunity for investment and others expressing concerns about its volatility.

Generated by AI

Nexalin Technology

Social

Aug 31

Bullish· May 22

Bearish· May 22

Announcements· Feb 5

Technical Analysis· Oct 8

Regulars· Oct 8

Newcomers· Aug 31

Nexalin appoints Robert DiTota as senior strategic advisor

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

Nexalin Announces 1-for-30 Reverse Stock Split Approval

Nexalin Technology approves 1-for-30 reverse stock split

Also Discussed

Nexalin Technology, Inc. Common Stock

Company Information

Location

Social

Aug 31

Bullish· May 22

Bearish· May 22

Announcements· Feb 5

Technical Analysis· Oct 8

Regulars· Oct 8

Newcomers· Aug 31

Nexalin appoints Robert DiTota as senior strategic advisor

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

Nexalin Announces 1-for-30 Reverse Stock Split Approval

Nexalin Technology approves 1-for-30 reverse stock split

Also Discussed